GSK-340 is a BET inhibitor with high affinity and significant selectivity for BD2 from BRD4 with a pIC50 of 7.2. GSK-340 inhibits MCP-1 release in Lipopolysaccharide ( HY-D1056 ) treated PBMCs and whole blood with the pIC50 of 7.4 and 6.0, respectively. GSK-340 has immunomodulatory activity.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Epigenetic Reader Domain
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。